Theranostic Potential of Copper-64 ATSM Targeting MTHFD2: An In Silico Perspective on Hypoxia-Selective Imaging and Therapy
Cell Biochemistry and Biophysics · 2025
DOI: 10.1007/s12013-025-01732-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biochemistry and Biophysics, 2025. Verfasst von Abdulsalam Abuelsamen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Imaging and radiography Department, Faculty of Allied Medical Sciences, Aqaba University of Technology, Aqaba, Jordan. a.abuelsamen@gmail.com. Hauptthemen laut MEDLINE: Methylenetetrahydrofolate Dehydrogenase (NADP), Aminohydrolases, Thiosemicarbazones, Multifunctional Enzymes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 112 Literaturangaben.
Abstract (Originalsprache)
Hypoxia is a hallmark of the tumor microenvironment, leading to metabolic reprogramming and therapeutic resistance. The enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) supports hypoxia adaptation, making it an attractive target for cancer treatment. Copper-64 diacetyl-bis(N4-methylthiosemicarbazone) (64Cu-ATSM) exhibits selective hypoxia uptake, positioning it as a promising theranostic agent for imaging and treating hypoxic tumors. In this study, we employed molecular docking and molecular dynamics (MD) simulations to evaluate the binding, stability, and dynamic behavior of 64Cu-ATSM within the MTHFD2 active site. Docking analysis revealed strong binding affinity (ΔGbind = -7.91 kcal/mol) with stable hydrogen bonding to key residues. MD simulations, assessed via root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), radial distribution function (RDF), solvent-accessible surface area (SASA), dynamic cross-correlation maps (DCCM), and 2D principal component analysis (2D-PCA), confirmed ligand stability. MM-PBSA and per-residue decomposition analyses identified ARG43, TYR84, ASN87, LYS88, GLN132, GLY310, GLY313, and PRO314 as key contributors to ligand stabilization. These findings support 64Cu-ATSM as a potential MTHFD2-targeting theranostic agent. However, in vitro and in vivo studies are needed to validate its therapeutic efficacy, pharmacokinetics, and clinical relevance for hypoxia-selective cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Imaging and radiography Department, Faculty of Allied Medical Sciences, Aqaba University of Technology, Aqaba, Jordan. a.abuelsamen@gmail.com.
- Department of Pharmacy, Faculty of Pharmacy, Jadara University, P.O.Box 733, Irbid, Jordan.
- Michael Sayegh Faculty of Pharmacy, Aqaba University of Technology, Aqaba, Jordan. Mohd.althiabat@gmail.com.
- General Education Department, Skyline University College, Sharjah, P. O. Box 1797, UAE.
- College of Engineering and Technology, American University of the Middle East, Egaila, Kuwait.
- Michael Sayegh Faculty of Pharmacy, Aqaba University of Technology, Aqaba, Jordan.
Zitieren
APA
Abuelsamen, A., Alhawarri, M. B., Al-Thiabat, M. G., Makhadmeh, G. N., AlZoubi, T., Alrimawi, B. H., & Khaleel, M. A. (2025). Theranostic Potential of Copper-64 ATSM Targeting MTHFD2: An In Silico Perspective on Hypoxia-Selective Imaging and Therapy. Cell Biochemistry and Biophysics. https://doi.org/10.1007/s12013-025-01732-3
Vancouver
Abuelsamen A, Alhawarri MB, Al-Thiabat MG, Makhadmeh GN, AlZoubi T, Alrimawi BH, et al. Theranostic Potential of Copper-64 ATSM Targeting MTHFD2: An In Silico Perspective on Hypoxia-Selective Imaging and Therapy. Cell Biochemistry and Biophysics. 2025. doi:10.1007/s12013-025-01732-3
BibTeX
@article{Abuelsamen2025,
author = {Abuelsamen, Abdulsalam and Alhawarri, Maram B and Al-Thiabat, Mohammad G and Makhadmeh, Ghaseb N and AlZoubi, Tariq and Alrimawi, Bilal Harieth and Khaleel, Mohammad A},
title = {Theranostic Potential of Copper-64 ATSM Targeting MTHFD2: An In Silico Perspective on Hypoxia-Selective Imaging and Therapy},
journal = {Cell Biochemistry and Biophysics},
year = {2025},
doi = {10.1007/s12013-025-01732-3}
}
EUVIMED